INS and type 2 diabetes mellitus: Subsequent clinical studies during the 2000s showed a glucose-lowering authority of DPP4 inhibitors in humans with type 2 diabetes as monotherapy or in combination with other therapies, i.e., metformin, sulfonylureas, tiazolidinediones, or exogenous insulin.